Shots: Noxopharm plans to seek approval to test its Veyonda (idronoxil) on COVID-19 patients in the US, following the research of Hudson Institute about the MOA of idronoxil that holds […]readmore
Tags : Clinical Study
Shots The company has commenced P-I clinical study assessing its vaccine candidate vs PBO in 144 healthy adults, aged 18-59yrs, with two different dosages of the vaccine candidate, conducted in […]readmore
Shots: Novavax deploys expertise of the Nucleus to commence P-I clinical study assessing NVX-CoV2373 for the first confirmed COVID-19 vaccines study outside the US. The P-I study is expected to […]readmore
Shots: The clinical study will evaluate the safety and efficacy of Virazole + SOC in hospitalized patients aged ≥18yrs. with respiratory distress due to COVID-19 The clinical study has been […]readmore
Shots: Novavax has identified a coronavirus vaccine candidate, NVX-CoV2373 utilizing its nanoparticle technology and will initiate a first-in-human trial in mid-May with its anticipated immunogenicity and safety results in July. […]readmore
Shots: Chugai has filed a clinical trial notification with the PMDA to conduct a P-III clinical study of Actemra (tocilizumab, IV, 80mg/200mg/400mg) to treat hospitalized patients with severe COVID19 pneumonia […]readmore
Shots: The US FDA has approved the P-III clinical study assessing Actemra (tocilizumab, IV) + SOC vs PBO + SOC in adult patients hospitalized with severe COVID-19 pneumonia with its […]readmore
Shots: The clinical study involves assessing HeadaTerm TENS therapy in patients that were divided into two groups: a sham group & a verum group, both the groups underwent therapy for […]readmore
Shots: The clinical study involves assessing the PK, efficacy, and safety of CT-P13 SC vs CT-P13 IV in 131 patients with active CD & UC for 1yr. Following loading doses […]readmore
Biosimilars
AffaMed Therapeutics’ AMT901 (biosimilar, trastuzumab) Receives NMPA’s Approval to Initiate
Shots: The NMPA has granted CTA approval to AffaMed to conduct a clinical study evaluating AMT901/ SB3, a biosimilar referencing Roche’s Herceptin. The company is preparing for clinical study with […]readmore